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Fifteen isolates of Klebsiella pneumoniae producing extended-spectrum b-lactamases (ESBLs) isolated during
a nosocomial outbreak were studied. The strains belonged to the same clonal type, as shown by pulsed-field gel
electrophoretic analysis of chromosomal DNA. All the isolates were resistant to extended-spectrum cephalo-
sporins, aztreonam, gentamicin, and fluoroquinolones and were susceptible to carbapenems, tobramycin,
netilmicin, and amikacin. None of the isolates expressed the OmpK36 porin. Eight isolates, for which the MICs
of cefoxitin were >64 mg/ml, showed a diminished level or no expression of a 35-kDa porin. The MICs of
meropenem, cefotaxime, and cefpirome were three to eight times higher for porin-deficient isolates than for
isolates expressing the 35-kDa porin, but the MICs of imipenem increased two times for porin-deficient isolates
compared to those for isolates expressing the porin. This MIC increase reverted to a level similar to that for
the parental strain when porin-deficient isolates were transformed with the gene coding for the K. pneumoniae
porin OmpK36. It is concluded that the high level of resistance to cefoxitin and the increase in the MICs of
meropenem, cefotaxime, and cefpirome for the ESBL-producing K. pneumoniae isolates studied are associated
with porin deficiency.
Klebsiella pneumoniae is an important human pathogen that
has been associated in recent decades with nosocomial out-
breaks. After the use of extended-spectrum cephalosporins,
extended-spectrum b-lactamase (ESBL)-producing K. pneu-
moniae has become an increasingly serious problem worldwide
(3, 11, 12, 25). This class of b-lactamases consists of plasmid-
mediated enzymes that are able to hydrolyze expanded-spec-
trum cephalosporins and monobactams. In K. pneumoniae ce-
foxitin resistance may be due to b-lactamase production (7, 24)
or the loss of porins (15, 23, 30).
Porins are outer membrane proteins (OMPs) that allow the
nonspecific diffusion of small molecules into the bacterial cell.
Most of the studies about OMPs have been carried out with
Escherichia coli, in which two major porins (OmpC and OmpF)
have been characterized. Loss of either of them has been re-
lated to antibiotic resistance (21). Decreased permeability
can produce significant levels of resistance that may be
increased when it is combined with enzymatic inactivation
(21). In K. pneumoniae, two main porins have been charac-
terized: OmpK35 (the homolog of OmpF) and OmpK36 (the
homolog of OmpC) (1, 10). Recently, loss of the OmpK36
porin has been associated with both cefoxitin resistance and
increases in cephalosporin and quinolone MICs (15). The as-
sociation between the loss of porins and increased MICs of
carbapenems has recently been described for K. pneumoniae
producing a plasmid-mediated AmpC-like b-lactamase (2, 16).
Expression of OmpK36 and/or inactivation of AmpC abolished
carbapenem resistance in this particular type of strain (16).
From May 1993 to June 1995, a nosocomial outbreak due to
K. pneumoniae producing ESBL involved 150 patients in our
hospital (25). During the outbreak, 4% of the ESBL-producing
K. pneumoniae isolates showed high levels of resistance to ce-
foxitin (MIC, .64 mg/ml). The aim of this study was to analyze
the mechanism of cefoxitin resistance among these strains.
MATERIALS AND METHODS
Bacterial isolates. Fifteen strains of ESBL-producing K. pneumoniae isolated
from 12 colonized or infected patients during the outbreak period were studied.
Eight of them were highly cefoxitin resistant (MICs, $64 mg/ml), for four strains
cefoxitin MICs were between 16 and 32 mg/ml, and the remaining three strains
were cefoxitin susceptible (MICs, between 2 and 4 mg/ml). These last three
isolates were recovered together with highly resistant isolates from a pharyngeal
swab, catheter, and blood of three patients, respectively.
Susceptibility studies. MICs were determined by the microdilution method
(19) and the E-test (AB Biodisk, Solna, Sweden). The following antibiotics were
tested: amikacin, amoxicillin, amoxicillin-clavulanic acid (2:1), aztreonam, cefo-
taxime, cefoxitin, cefoxitin-clavulanic acid (2:1), cefpirome, ceftazidime, ceftazi-
dime-clavulanic acid (2:1), ciprofloxacin, gentamicin, imipenem, meropenem,
netilmicin, ofloxacin, piperacillin, piperacillin-tazobactam (2:1), sparfloxacin,
and tobramycin.
Antimicrobial susceptibility tests with strains CSUB10R(pSHA19) and
CSUB10R(pSHA20) (see below) were performed in Mueller-Hinton broth
(Izasa, Barcelona, Spain) supplemented with 50 mg of kanamycin (Sigma, Ma-
drid, Spain) per ml and 25 mg of chloramphenicol (Sigma) per ml.
The presence of broad extended-spectrum b-lactamase production was studied
by the double-disk synergy test (14) and by the E-test method (AB Biodisk).
Conjugation experiments. Transfer of resistance to expanded-spectrum ceph-
alosporins and monobactams from K. pneumoniae CSUB10S and CSUB10R to
E. coli J53-2 was carried out by conjugation in broth as described previously (15).
Ampicillin and rifampin (100 mg/ml each) were used as selective agents.
Isoelectric focusing. Strains were grown for 4 h in Luria broth. The growing
bacteria were pelleted, resuspended in distilled water, and sonicated. Extract
purifications were performed by ultracentrifugation (14). Isoelectric focusing of
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b-lactamase extracts was done with the PhastSystem apparatus (Pharmacia,
Uppsala, Sweden) in polyacrylamide gels with a pH range of 3 to 9 (PhastGel 3-9;
Pharmacia). The gels were stained with 500 mg nitrocefin (Oxoid, Hampshire,
England) per ml, and pIs were determined by comparison with different b-lac-
tamases with known pIs.
Typing methods. Biotyping was carried out with API 20E galleries (bio-
Mérieux, Balmes les Grottes, France) according to the manufacturer’s instruc-
tions and with MicroScan NegCombo 6I panels (DADE International, Inc., West
Sacramento, Calif.).
Macrorestriction analysis of chromosomal DNA was done by pulsed-field gel
electrophoresis (PFGE) by previously described procedures (8). DNA restriction
was done with XbaI (New England Biolabs, Madrid, Spain) following the man-
ufacturer’s recommendations. PFGE was performed in a CHEF-DR III appa-
ratus (Bio-Rad, Hercules, Calif.) for 23 h at 14°C with pulse times ranging from
1 to 30 s at 6 V/cm.
OMP isolation and analysis. For porin isolation, we used a combination of the
two methods for the isolation of E. coli porins (20, 22). Cell envelopes were
treated with trypsin and subjected to differential solubilization as described in
detail by Alberti et al. (1). The isolated porins were separated by sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and were electro-
phoretically transferred to Immobilon P membranes (Millipore, Barcelona,
Spain) by using the buffers and conditions described by Towbin et al. (29). The
membranes were stained with Ponceau red, and bands of interest were excised
separately, destained, and sequenced in an Applied Biosystems 470 gas-phase
sequencer (kindly done by the Servicio de Secuenciación of the Centro de
Investigaciones Biológicas del Consejo Superior de Investigaciones Cientificas,
Madrid, Spain).
K. pneumoniae strains were grown in Mueller-Hinton broth and sonicated, and
cell envelopes were recovered by ultracentrifugation. After treatment with so-
dium N-lauroyl sarcosinate (Sigma, Madrid, Spain), the OMPs were collected by
ultracentrifugation (15). Electrophoretic analysis of OMP by SDS-PAGE was
performed in 11% acrylamide–0.35% bisacrylamide–0.1% SDS by using Laem-
mli’s buffers. The samples were boiled for 5 min in Laemmli’s buffer before
electrophoresis. The gels were stained with Coomassie blue.
Transfer and expression of ompK36 gene. Plasmid pSUV7, containing the gene
coding for the OmpK36 porin, and plasmid pFR167, containing a truncated
ompK36 gene, have been described previously (15). These plasmids include a
kanamycin resistance cassette to allow their selection in the multidrug-resistant
background of strain CSUB10R. Briefly, the kanamycin resistance cassette of
plasmid pCSI2 (6) was obtained as an XbaI-XbaI fragment and was cloned into
the unique XbaI sites of plasmids pSUV7 and pFR167. The result was plasmid
pSHA19, which contains the ompK36 gene, and plasmid pSHA20, which contains
a truncated ompK36 gene. The modified plasmids were introduced by electro-
poration into strain CSUB10R, and the transformed CSUB10R strains carrying
the cloned porin genes were selected as kanamycin-resistant strains. DNA
isolation, enzyme restrictions, and ligation were performed by standard pro-
cedures (28).
RESULTS
Susceptibility testing. All the strains tested were resistant to
amoxicillin (MIC, .256 mg/ml) and piperacillin (MICs, 128 to
.256 mg/ml). The amoxicillin-clavulanic acid MICs ranged
from 4 to 16 mg/ml, whereas the piperacillin-tazobactam
MIC range was from 2 to .256 mg/ml. For cefoxitin-resis-
tant strains, the addition of clavulanic acid did not result in a
reversion to cefoxitin susceptibility. Amikacin (MIC, 2 mg/ml),
tobramycin (MIC range, 0.5 to 1 mg/ml), and netilmicin (MIC
range, 0.5 to 2 mg/ml) were active against all K. pneumoniae
isolates. All the isolates were resistant to gentamicin (MIC
range, 8 to 16 mg/ml).
Table 1 presents the MICs of 11 antibiotics for cefoxitin-
susceptible and -resistant isolates cultured from the same pa-
tient and the MICs of these antibiotics for CSUB10R
(pSHA19) and CSUB10R(pSHA20) containing the entire and
truncated ompK36 porin genes, respectively. For cefoxitin-re-
sistant isolates, the MICs of cefotaxime (3 to 5 dilution steps),
cefpirome (5 to 7 dilution steps), meropenem (5 to 6 dilution
steps), imipenem (2 dilution steps), and ceftazidime-clavulanic
acid (2 dilution steps) were higher than those for the cefoxitin-
susceptible strains. The quinolone MICs for cefoxitin-resistant
strains were always from 1 to 3 dilution steps higher than those
for cefoxitin-susceptible strains. For strain CSUB10R, the ce-
foxitin resistance and the increased MICs of meropenem,
cefotaxime, cefpirome, and ceftazidime-clavulanic acid re-
verted to MICs which were similar to those for strain
CSUB10S after cloning of the ompK36 gene into the strain
[strain CSUB10R(pSHA19)].
Table 2 presents the MICs of 11 antibiotics for K. pneu-
moniae isolates with different degrees of resistance to cefoxitin.
For isolates for which the cefoxitin MIC was $64 mg/ml, the
cefpirome and cefotaxime MICs increased and the mero-
penem MIC was 4 to 32 times higher than those for strains for
which cefoxitin MICs were ,64 mg/ml. The MICs of norfloxa-
cin (MIC range, 64 to 128 mg/ml), ofloxacin (MIC range, 4 to
8 mg/ml), ciprofloxacin (MIC range, 2 to 8 mg/ml), or spar-
floxacin (MIC range, 1 to 4 mg/ml) cannot be related to the
degree of cefoxitin resistance.
E. coli transconjugants, with K. pneumoniae CSUB10R or
CSUB10S used as donors, were resistant to expanded-spec-
trum cephalosporins as a result of ESBL production. Cefoxitin
resistance and increased carbapenem MICs were not trans-
ferred to E. coli by conjugation of the donor.
b-Lactamase study. The production of ESBLs was demon-
strated in all the strains by the double-disk synergy test and by
at least a threefold reduction in the ceftazidime MIC when
clavulanic acid was added. Isoelectric focusing of b-lactamase
extracts showed that all but one of the isolates produced a
TABLE 1. Characteristics of cefoxitin-resistant and -susceptible ESBL-producing K. pneumoniae pairs isolated from three patients and the





Patient 2 Patient 3
CSUB10R CSUB10S CSUB8R CSUB8S CSUB9R CSUB9S
Cefoxitin 128 2 0.6 128 128 4 128 4
Cefotaxime .256 4 32 .256 .256 64 256 4
Cefpirome .256 2 8 .256 256 8 128 2
Ceftazidime .256 .256 .256 .256 .256 .256 .256 .256
Ceftazidime-clavulanic acid 2 0.5 0.5 2 4 1 2 0.5
Aztreonam .256 .256 .256 .256 .256 .256 .256 .256
Imipenem 0.5 0.12 0.06 0.5 0.5 0.12 0.5 0.12
Meropenem 2 0.06 0.12 2 2 0.03 2 0.03
Ofloxacin 4 2 0.5 4 4 2 8 4
Ciprofloxacin 4 0.5 0.5 4 2 1 2 2
Sparfloxacin 4 1 0.25 4 2 1 2 1
Porin expression 2 1 1 2 2 1 2 1
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single enzyme: nine produced an enzyme with a pI of 8.2, and
five produced an enzyme with a pI of 7.6. The remaining
isolate produced two b-lactamases with pIs of 7.6 and 8.2. No
relationship between pI and the degree of cefoxitin resistance
was found. The cefoxitin-resistant and -susceptible strains iso-
lated from the same patients had b-lactamases with identical
pIs. Aztreonam MICs showed variations according to the b-
lactamase pI. For K. pneumoniae isolates producing a b-lacta-
mase with a pI of 8.2 the aztreonam MIC (MIC range, 128 to
.256 mg/ml) was higher than that for those producing a b-lac-
tamase with a pI of 7.6 (MIC range, 0.5 to 32 mg/ml).
Typing methods. All 15 isolates exhibited the same biotype
by testing both with the API 20E and the MicroScan systems.
A major PFGE pattern after chromosomal DNA restriction
with XbaI was found (Fig. 1). This pattern showed only five
minor variations (subtypes A1 to A5), and overall, the isolates
were considered to be clonally related to the dominant strain
found during the outbreak. There was no relationship between
the PFGE subtypes of the strains and porin expression. Pairs of
cefoxitin-resistant and cefoxitin-susceptible isolates from three
patients also had identical PFGE patterns.
OMP analysis. SDS-PAGE analysis of the OMPs showed
that all the clinical isolates expressed two OMPs of about 32
and 45 kDa and that isolates for which cefoxitin MICs were
,128 mg/ml also expressed an additional OMP of about 35
kDa (Fig. 2 and 3). The 32-kDa protein is probably the K. pneu-
moniae homolog of E. coli OmpA because of its increased mo-
bility (molecular mass, about 22 kDa) in samples solubilized at
37°C (data not shown). The 45-kDa band was isolated from
strain CSUB10R (Fig. 4) by a porin isolation method, and
N-terminal analysis of its first 12 amino acids showed that it
had complete identity with K. pneumoniae LamB. The porin
isolation method, when applied to strain CSUB10S, produced the
35- and 45-kDa proteins (Fig. 4). After SDS-PAGE separation,
they were transferred to a polyvinylidene difluoride mem-
brane, and their N termini were sequenced. Sequence analysis
confirmed that 45-kDa protein corresponds to LamB, while the
35-kDa sequence demonstrated that it is a nonspecific pore
protein (porin). The complete identity of the first amino acids
of the OmpK36 and OmpK35 porins from K. pneumoniae and
other enterobacterial porins (13) prevented assignment of the
35-kDa porin to either one of the two porins of the species.
This 35-kDa porin was absent from isolates for which the ce-
foxitin MIC was 128 mg/ml (Fig. 2 and 3). Expression of this
porin, as judged by SDS-PAGE, was reduced in isolates for
which cefoxitin MICs were 64 mg/ml, while sufficient expres-
sion of this porin was found in isolates for which cefoxitin
MICs were 32 mg/ml (Fig. 2 and 3).
DISCUSSION
Nosocomial outbreaks due to ESBL-producing enterobacte-
ria have become a serious problem worldwide (12, 17, 18).
Treatment of infections due to these microorganisms is a dif-
ficult task because b-lactamase production inactivates most of
the b-lactam antibiotics, and these microorganisms are usually
resistant to other antibiotic groups such as aminoglycosides
and quinolones. Cephamycins such as cefoxitin are active in
vitro against these strains, but this agent can select porin-de-
ficient mutants with increased levels of resistance to cefoxitin
and other cephalosporins (15, 23, 30). Combinations of a b-lac-
tam and a b-lactamase inhibitor are not always active against
these microorganisms (27). Carbapenems also remain a good
option, but the emergence of imipenem-resistant strains of
Pseudomonas aeruginosa and other gram-negative bacilli could
occur when imipenem is widely used (17). In addition, it has
recently been described that K. pneumoniae becomes carba-
penem resistant as a result of porin deficiency and plasmid-
mediated AmpC-like b-lactamases (2, 16).
FIG. 1. PFGE of total DNA from K. pneumoniae cut with XbaI. Lane 1,
PFGE Molecular Weight Marker (New England Biolabs); Lanes 2 and 3 and
lanes 6 and 7, porin-sufficient isolates; lanes 4 and 5, strains with diminished
expression of porin; lanes 8 to 10, porin-deficient isolates; lanes 11 and 12, lanes
13 and 14, and lanes 15 and 16, pairs of porin-deficient and porin-sufficient
isolates (in the respective pairs of lanes) from three patients.
TABLE 2. Characteristics of nine K. pneumoniae strains with different degrees of resistance to cefoxitin isolated from nine patients
Antimicrobial agent
MIC (mg/ml)
CSUB3 CSUB7 CSUB1 CSUB6 CSUB4 CSUB5 CSUB2 CSUB11 CSUB12
Cefoxitin 16 16 32 32 64 64 128 128 128
Cefotaxime 0.25 4 2 2 128 64 4 .256 32
Cefpirome 4 2 1 2 64 32 16 .256 32
Ceftazidime 16 64 4 128 .256 64 8 .256 .256
Ceftazidime-clavulanic acid 1 1 0.5 2 2 1 0.5 4 2
Aztreonam 1 128 1 128 32 16 2 .256 .256
Imipenem 0.12 0.12 0.06 0.12 0.25 0.12 0.12 0.5 0.5
Meropenem 0.03 0.03 0.03 0.03 0.12 0.12 0.5 2 1
Ofloxacin 8 8 8 8 8 8 8 4 4
Ciprofloxacin 4 4 4 8 4 4 8 2 2
Sparfloxacin 4 2 4 4 4 2 4 1 1
Porin expression 1 1 1 1 6a 6 2 2 2
a 6, reduced level of porin expression.
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The loss of porins OmpC and OmpF as a cause of antibiotic
resistance has been noted in several reports, especially for
E. coli and Salmonella typhimurium (21). In K. pneumoniae,
loss of both the OmpK35 and the OmpK36 porins has been
shown to cause increased levels of resistance to cefoxitin and
extended-spectrum cephalosporins and probably contributes to
ciprofloxacin resistance (4, 15, 30). This resistance phenotype
reverted when the strain expressed OmpK36 porin in its outer
membrane after cloning of the ompK36 gene (15).
During an outbreak caused by K. pneumoniae producing
ESBLs in our hospital (25), 4% of the isolates were highly
resistant to cefoxitin (MICs, $128 mg/ml). Porin deficiency was
associated with this resistance phenotype, and the diminished
level of expression of this protein was related to a cefoxitin
MIC of 64 mg/ml. In addition, porin deficiency was associated
with increased MICs of cefotaxime and cefpirome, probably
because in porin-deficient mutants the uptake of extended-
spectrum cephalosporins is less effective than that in porin-
sufficient strains (23). Thus, the combination of the decreased
outer membrane permeation and the hydrolytic effect of ESBLs
increased the MICs of expanded-spectrum cephalosporins for
the resistant strains studied.
The six porin-deficient strains showed 8- to 32-fold de-
creased susceptibilities to meropenem but only 2-fold de-
creased susceptibilities to imipenem. The MICs of meropenem
were four times higher than those of imipenem. When isolate
CSUB10R was transformed with a gene coding for the OmpK36
K. pneumoniae porin, this resistance phenotype reverted and
the MICs of carbapenems for this strain were similar to those
for the CSUB10S strain that expresses the OmpK36 porin and
that was isolated from the same clinical sample as strain
CSUB10R. These findings suggest a main role of this porin in
the decreased susceptibility of K. pneumoniae to meropenem.
The association between the loss of porins and imipenem
resistance has recently been described in K. pneumoniae pro-
ducing plasmid-mediated AmpC-like b-lactamase (2, 16). In
other members of the family Enterobacteriaceae such as Entero-
bacter cloacae and Proteus rettgerii, resistance to carbapenems
has been related to diminished outer membrane permeability
and hydrolysis by the overproduced chromosomal b-lactamase
(5, 26). It seems that, like in E. cloacae, the level of meropenem
susceptibility in K. pneumoniae is more dependent on porin
expression, whereas imipenem susceptibility is less affected by
this resistance mechanism and is more dependent on the pro-
duction of secondary b-lactamases of the AmpC type (2, 5, 16,
26). It is difficult to determine the exact mechanism by which
the loss of porins results in decreased meropenem susceptibil-
ity. In independent studies, we have shown that strain
CSUB10R produces an active efflux mechanism causing de-
creased levels of accumulation of fluoroquinolones in the cell
(unpublished observation). A similar mechanism has been ob-
served in P. aeruginosa with reduced susceptibility to mero-
penem when the efflux system MexAB-OprM is expressed.
Experiments are in progress to determine a possible link be-
tween the efflux of meropenem and decreased susceptibility to
this carbapenem.
In a comparison of the three pairs of cefoxitin-susceptible
and -resistant strains isolated from the same patient, from two-
to eightfold increases in the quinolone MICs were found. In
addition, for strain CSUB10R from patient 1, a two- to four-
fold decrease in the quinolone MICs was observed after the
OmpK36 porin was introduced into this strain. This relation-
ship has been reported previously (9, 15, 30), suggesting that
loss of porin can contribute to quinolone resistance. However,
this cross-resistance did not correlate with the degree of ce-
foxitin resistance in the other K. pneumoniae isolates studied.
The relative importance of the possible mechanisms involved
in quinolone resistance are under investigation; however, mu-
tations have been detected in the quinolone resistance-deter-
mining region of gyrA but not that of parC in both CSUB10R
and CSUB10S strains (unpublished observations); in addition,
an active efflux mechanism causing a decreased level of accu-
mulation of fluoroquinolones was detected in strain CSUB10R.
FIG. 2. SDS-PAGE analysis of outer membrane proteins of K. pneumoniae
isolates. Lane MW, molecular weight standard (in kilodaltons); lanes 1, 3, 6, and
7, porin-expressing isolates; lanes 4 and 5, isolates with diminished levels of porin
expression; lane 2, porin-deficient isolate.
FIG. 3. SDS-PAGE analysis of outer membrane proteins of K. pneumoniae
isolates. Lane MW, molecular mass standard (in kilodaltons); lanes 1 and 2, lanes
3 and 4, and lanes 5 and 6, porin-sufficient and porin-deficient isolates (in the
respective pairs of lanes) from the same patients; lanes 7 and 8, porin-deficient
isolates.
FIG. 4. SDS-PAGE analysis of OMPs and porins from strains CSUB10S
(lanes 1 and 3) and CSUB10R (lanes 2 and 4). Lanes 1 and 2, OMP; lanes 3 and
4, porins. Numbers on the left side correspond to the approximate molecular
masses of the proteins (in kilodaltons).
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By PFGE there was a clonal relationship among the highly
cefoxitin-resistant K. pneumoniae isolates; moreover, these iso-
lates belonged to the same clone as the epidemic strain (which
was cefoxitin susceptible) responsible for the outbreak. This
suggests the in vivo selection of porin-deficient mutants from a
common ancestor, i.e., the epidemic strain, as reported previ-
ously (15, 23).
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and F. Gudiol. Epidemiology and successful control of a large outbreak due
to Klebsiella pneumoniae producing extended-spectrum b-lactamases. Anti-
microb. Agents Chemother. 42:53–58.
26. Raimond, A., A. Traverso, and H. Nikaido. 1991. Imipenem- and mero-
penem-resistant mutants of Enterobacter cloacae and Proteus rettgeri lack
porins. Antimicrob. Agents Chemother. 35:1174–1180.
27. Rice, L. B., L. L. Carias, R. A. Bonomo, and D. M. Shlaes. 1996. Molecular
genetics of resistance to both ceftazidime and b-lactam–b-lactamase inhib-
itor combinations in Klebsiella pneumoniae and in vivo response to b-lactam
therapy. J. Infect. Dis. 173:151–158.
28. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a
laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold
Spring Harbor, N.Y.
29. Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of
proteins from polyacrylamide gels to nitrocellulose sheets: procedure and
some applications. Proc. Natl. Acad. Sci. USA 76:4350–4354.
30. van der Klundert, J. A. M., M. H. van Gestel, G. Meerdink, and S. de Marie.
1988. Emergence of bacterial resistance to cefamandole in vivo due to outer
membrane protein deficiency. Eur. J. Clin. Microbiol. Infect. Dis. 7:776–777.
1640 ARDANUY ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 on A
ugust 1, 2017 by U
S
E
/B
C
T
A
.G
E
N
 U
N
IV
E
R
S
IT
A
R
IA
http://aac.asm
.org/
D
ow
nloaded from
 
